Unveiling the omics tapestry of B-acute lymphoblastic leukemia: bridging genomics, metabolomics, and immunomics by Yin Le, Shicong Zhu, Hongling Peng, Zhihua Wang

“…Abstract Acute B-lymphoblastic leukemia (B-ALL) is a highly heterogeneous hematologic malignancy, characterized by significant molecular differences among patients as the disease progresses. …”
Get full text

Risk Factors and Predictive Model for Disseminated Intravascular Coagulation in Patients with Multiple Myeloma by Rong Bao MM, Mengtong Fan MM, Min Hu MM, Ling Li BD,   Hasichaolu BD

“…Objectives Multiple myeloma (MM) is a hematologic malignancy comprising approximately 10% of all blood cancers. …”
Get full text

Cryo-thermal therapy reshaped the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy by Shicheng Wang, Peng Peng, Junjun Wang, Zelu Zhang, Ping Liu, Lisa X. Xu

“…Abstract Background Adoptive cell therapies (ACT) exhibit excellent efficacy in hematological malignancy. However, its application in solid tumors still has many challenges partly due to the tumor immune microenvironment. …”
Get full text

Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study by Nawal Salahuddin, Lama Amer, Mini Joseph, Alya El Hazmi, Hassan Hawa, Khalid Maghrabi

“…On multivariate regression analysis, failure to deescalate was significantly predicted by hematologic malignancy OR 3.3 (95% CI 1.4–7.4) p<0.004, fungal sepsis OR 2.7 (95% CI 1.2–5.8) p=0.011, multidrug resistance OR 2.9 (95% CI 1.4–6.0) p=0.003, baseline serum procalcitonin OR 1.01 (95% CI 1.003–1.016) p=0.002, and SAPS II scores OR 1.01 (95% CI 1.004–1.02) p=0.006. …”
Get full text

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice by Dai Fukumura, Rakesh K Jain, Jun Ren, Xinyue Dong, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette

“…Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. …”
Get full text

Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy by Kohei Kasahara, Masahiro Onozawa, Naohiro Miyashita, Emi Yokohata, Miho Yoshida, Minoru Kanaya, Mizuha Kosugi-Kanaya, Ryo Takemura, Shojiro Takahashi, Junichi Sugita, Akio Shigematsu, Mutsumi Takahata, Shinichi Fujisawa, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima

“…Simultaneous onset of cytogenetically unrelated hematological malignancies that each have a different disease status is a rare phenomenon but is important to diagnose for a correct understanding of the disease status and for establishing an appropriate treatment strategy.…”
Get full text

The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells by Minghao Sui, Tiantian Liu, Xuanli Song, Ji Li, Han Ding, Yuqian Liu, Xinyu Wang, Huimin Liu, Yuchan Xue, Jianni Qi, Miao Zhang, Songbo Zhao, Qiang Zhu

“…Chimeric antigen receptor (CAR) T cells have encouraging results in the treatment of hematological malignancies. However, CAR-T therapy still faces numerous challenges against solid tumors, such as hepatocellular carcinoma (HCC), owing to heterogeneous antigen expression in tumor cells, limited persistence of CAR-T cells, etc. …”
Get full text

Polymorphisms in immunosuppression-related genes are associated with AML by Mingying Li, Mingying Li, Jingjing Ye, Jingjing Ye, Mengyuan Chang, Mengyuan Chang, Lei Feng, Lei Feng, Tingting Liu, Tingting Liu, Di Zhang, Di Zhang, Yuyan Wu, Yuyan Wu, Yuechan Ma, Yuechan Ma, Guangqiang Meng, Guangqiang Meng, Chunyan Ji, Chunyan Ji, Tao Sun, Tao Sun

“…BackgroundAcute myeloid leukemia (AML) is a hematologic malignancy with poor overall survival (OS). The immunosuppressive microenvironment significantly impacts AML development and chemoresistance. …”
Get full text

Large-scale manufacturing and characterization of CMV-CD19CAR T cells by Stephen J Forman, Xiuli Wang, Ryan Urak, Miriam Walter, Min Guan, Tianxu Han, Vibhuti Vyas, Sheng-Hsuan Chien, Brenna Gittins, Mary C Clark, Sally Mokhtari, Angelo Cardoso, Don J Diamond, John Zaia, Ryotaro Nakamura

Get full text

Shift in the profile and prognostic implications in invasive fungal rhinosinusitis: experience of 10 years in a tertiary center by Raúl Mellidez-Acosta, Lidia Torres-García, Miguel Saro-Buendía, Natalia Jaramillo-Ángel, Javier Cabrera-Guijo, Catalina Bancalari-Díaz, Noelia Muñoz-Fernández, Lucas Fito-Martorell, Miguel Armengot-Carceller, Alfonso García-Piñero

“…The most frequents underlying conditions were hematological malignancies (76.5%) and solid organ transplantation (11.8%). …”
Get full text

Protocol for predicting the single-cell network-based gene activity landscape during human B cell development by Xin Huang, Xuetong Hou, Yizhen Li, Jun J. Yang, Jiyang Yu

Get full text

The Feature of Distribution and Clonality of TCR γ/δ Subfamilies T Cells in Patients with B-Cell Non-Hodgkin Lymphoma by Liang Wang, Meng Xu, Chunyan Wang, Lihua Zhu, Junyan Hu, Shaohua Chen, Xiuli Wu, Bo Li, Yangqiu Li

“…Restricted T-cell receptor (TCR) Vα/Vβ repertoire expression and clonal expansion of αβ T cells especially for putative tumor-associated antigens were observed in patients with hematological malignancies. To further characterize the γδ T-cell immune status in B-cell non-Hodgkin lymphoma (B-NHL), we investigated the distribution and clonality of TCR Vγ/Vδ repertoire in peripheral blood (PB), bone marrow (BM), and lymph node (LN) from patients with B-NHL. …”
Get full text

Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review by Umaima Abbas, Robin MacKenzie, Ushra Khan, Rija Fatima, Tzu-Fei Wang, Rong Luo, Caroline Hamm, Andrea Cervi

“…Results: Forty-two patients met the inclusion criteria; 20 (47.6%) had a solid organ malignancy while 22 (52.4%) had a hematologic malignancy. Within the first 7 days of VTE, 3 (7.1%) patients had a platelet count <25,000/μL, 9 (21.4%) had 25,000 to 50,000/μL, and 19 (45.2%) had 50,000 to 100,000/μL. …”
Get full text

Synchronous Occurrence of Splenic Pleomorphic Mantle Cell Lymphoma and Esophageal Adenocarcinoma with Overexpression of BCL1 Protein by Dominik Dabrowski, Roberto F. Silva, Michael Constantinescu, Rodney E. Shackelford, Nestor Dela Cruz, Eric X. Wei

“…We have reviewed previous reports of synchronic mantle cell lymphoma and other solid tumors or hematological malignancies in the literature.…”
Get full text

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia by Juan Li, Chunmei Ye, Hui Li, Jun Li

“…Objectives Acute T-cell lymphoblastic leukemia (T-ALL) is a severe hematologic malignancy with limited treatment options and poor long-term survival. …”
Get full text

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy by Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber

“…These data support the clinical development of ANV419 in solid tumors and hematological malignancies as monotherapy and in combination with checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. …”
Get full text

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients wit... by Charissa Wijnands, Peter G. A. Karel, Jolein Gloerich, Gad Armony, Anastasia Tzasta, Corrie M. de Kat Angelino, Luciano Di Stefano, Vincent Bonifay, Theo M. Luider, Martijn M. VanDuijn, Sandra J. Croockewit, Elizabeth A. de Kort, Daan A. R. Castelijn, Claudia A. M. Stege, Hans J. C. T. Wessels, Alain J. van Gool, Niels W. C. J. van de Donk, Joannes F. M. Jacobs

“…<b>Background/Objectives:</b> Multiple Myeloma (MM) is a hematologic malignancy caused by clonally expanded plasma cells that produce a monoclonal immunoglobulin (M-protein), a personalized biomarker. …”
Get full text

Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia by Le Jie Lee, Norfarazieda Hassan, Siti Zuleha Idris, Suresh Kumar Subbiah, Heng Fong Seow, Norhafizah Mohtaruddin, Kian Meng Chang, Raudhawati Osman, Hishamshah Mohd Ibrahim, Sheila Nathan, Maha Abdullah

“…Acute lymphoblastic leukemia (ALL) is a hematological malignancy mainly of B cell (B-ALL) and T cell (T-ALL) subtypes. …”
Get full text

Archived Cytogenetic Cell Pellets Used to Detect a BCR::ABL1 Driver Mutation Eight Years before Disease Presentation by Ramakrishnan Sasi, Michelle Spruill, Peter L. Perrotta

“…Such archived material may be useful for the retrospective studies needed to better understand the initiation and subsequent development of hematological malignancies. By identifying individuals who are at increased risk, it may be possible to initiate preventive measures or begin treatment at an earlier stage before disease progression.…”
Get full text

Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes by Yan-Hua Wang, Shotaro Hagiwara, Hiroshi Kazama, Yuki Iizuka, Norina Tanaka, Junji Tanaka

“…Multiple myeloma (MM) is an intractable hematological malignancy caused by abnormalities in plasma cells. …”
Get full text